| |
Phase 1
|
Phase 2
|
Total
|
p-value*
|
|---|
|
Survival
|
n
|
%
|
n
|
%
|
n
|
%
| |
|
TR deaths
|
9
|
2
|
4
|
1
|
13
|
2
|
0.1242
|
|
ICU deaths
|
106
|
26
|
67
|
21
|
173
|
24
|
<0.001
|
|
Hospital deaths
|
118
|
29
|
72
|
22
|
190
|
26
|
<0.001
|
|
6 m deaths
|
127
|
31
|
72
|
22
|
199
|
27
|
<0.001
|
|
Unknown at 6 m
|
179
|
44
|
39
|
12
|
218
|
30
| |
|
Total
|
408
|
100
|
325
|
100
|
733
|
100
| |
|
6 month outcome
|
n
|
%
|
n
|
%
|
n
|
%
| |
|
Favorable
|
75
|
18
|
181
|
56
|
256
|
35
|
<0.001
|
|
Unfavorable
|
154
|
38
|
105
|
32
|
259
|
35
|
|
Unknown
|
179
|
44
|
39
|
12
|
218
|
30
| |
|
Grand Total
|
408
|
100
|
325
|
100
|
733
|
100
| |
- Legend: *the tests were applied only on known values; 6 month outcome was measured by GOSE (Glasgow Outcome Scale extended) and dichotomized into favorable (GOSE score 7–8) and unfavorable (GOSE score 1–6) outcomes
